Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 13/20 | 0.71 |
| ▸ | RET | P07949 | 4/20 | 0.71 |
| ▸ | KDR | P35968 | 4/20 | 0.71 |
| ▸ | FLT3 | P36888 | 3/20 | 0.71 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.71 |
| ▸ | FLT1 | P17948 | 2/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.71 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.69 |
| ▸ | JAK3 | P52333 | 4/20 | 0.68 |
| ▸ | TLK2 | Q86UE8 | 4/20 | 0.68 |
| ▸ | SYK | P43405 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.68 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | FYN | P06241 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3912686 | 1.00 | PDGFRB (1.00) | PDGFRBPDPK1RETKDRFLT3 | |
| SCHEMBL5728403 | 0.89 | PDGFRB (0.80) | PDGFRBPDPK1RETKDRFLT3 | |
| SCHEMBL5728402 | 0.89 | PDGFRB (0.80) | PDGFRBPDPK1RETKDRFLT3 | |
| SCHEMBL5728408 | 0.83 | PDPK1 (0.76) | PDGFRBPDPK1RETKDRFLT3 | |
| SCHEMBL5373346 | 0.83 | PDPK1 (0.71) | PDGFRBPDPK1RETKDRFLT3 | |
| SCHEMBL18053 | 0.83 | PDPK1 (1.00) | PDGFRBPDPK1RETKDRFLT3 | |
| SCHEMBL13081202 | 0.83 | PDGFRB (0.80) | PDGFRBPDPK1RETKDRFLT3 | |
| SCHEMBL5727973 | 0.83 | PDPK1 (1.00) | PDGFRBPDPK1RETKDRFLT3 | |
| SCHEMBL19691 | 0.83 | PDPK1 (1.00) | PDGFRBPDPK1RETKDRFLT3 | |
| SCHEMBL18054 | 0.83 | PDPK1 (1.00) | PDGFRBPDPK1RETKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2003-05-01 | — | — | US | claimed |
| EP-1201765-A2 | Cellular kinases involved in cytomegalovirus infection and their inhibition | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-05-02 | — | — | EP | claimed |
| US-20170240522-A1 | BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2017-08-24 | — | — | US | disclosed |
| WO-2016041972-A1 | BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-03-24 | — | — | WO | disclosed |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
| US-7531665-B2 | Kinase inhibitors for the treatment of disease | ALLERGAN, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PFIZER INC | 2006-11-09 | — | — | US | disclosed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | disclosed |
| EP-0934931-A2 | 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators | Sugen, Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5886020-A | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5883113-A | TYROSINE KINASE INHIBITORS; ANTIPROLIFERATIVE AND ANTICARCINOGENIC AGENTS; DIABETES, ARTHRITIS, RESTENOSIS, ATHEROSCLEROSIS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5883116-A | ANTITUMOR AGENTS AND ENZYME INHIBITORS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5834504-A | MODULATING, INHIBITING ABNORMAL CELL PROLIFERATION; ENZYME INHIBITION | SUGEN, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0769947-A4 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | PDGFRB 2159/4885PDPK1 438/4885RET 4729/4885 |
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | CDC42BPG, CDC42BPB, CDC7 | PDGFRB 1923/4885PDPK1 185/4885RET 1445/4885 |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGES3 | PDGFRB 2095/4885PDPK1 2037/4885RET 2849/4885 |
| US-20170240522-A1 | BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS | INMT, IDO2, IDO1 | PDGFRB 2274/4885PDPK1 1142/4885RET 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.